olivLaw · US equity research
LifeMD, Inc. LFMD
Services-Offices & Clinics of Doctors of Medicine · SIC 8011 · Vertical: Services-Offices & Clinics of Doctors of Medicine (SIC 8011)
LifeMD is a direct-to-patient healthcare company offering virtual medical consultations and pharmacy services through a vertically integrated platform, with revenue built largely on recurring subscriptions. In 2026 the company cut its full-year guidance as it moved away from compounded GLP-1 drugs toward branded ones, and adjusted profitability remains under pressure. Telehealth revenue grew 25% in fiscal 2025, and second-quarter 2026 revenue reached 47.3 million USD.
At the close of 05 Nov 2026, LifeMD, Inc. (LFMD) stock was 2.29 USD (−6.53% on the day), with market capitalisation 110.4 m USD, dividend yield 2.81%, beta 1.73, 52-week range 2.08–5.27 USD. Latest reported quarter (Q2 2026): revenue of 47.3 m USD (−3.5% YoY), net income of -7.1 m USD, diluted EPS -0.16 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 43.3
- weak (30–45)
- Bollinger (20, 2)
- 2.01 – 2.60
- in the lower half of the band · %B 0.48 · band width 25.5%
- SMA 50 / 200
- 2.74 / 3.64
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.14 / -0.18
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −16.1% | −5.9% | −10.2 pp | — |
| 3 months | −32.6% | −4.6% | −28.0 pp | — |
| 6 months | −49.0% | +0.2% | −49.2 pp | — |
| Year to date | −32.8% | +7.4% | −40.3 pp | — |
| 1 year | −59.3% | +8.2% | −67.5 pp | −4.4% |
| 3 years | −68.7% | +68.4% | −137.1 pp | −51.1% |
| 5 years | −53.8% | +56.5% | −110.4 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 53.3 m | 5.5 m | 50.9 m | 49.0 m | 60.2 m | 7.1 m | 50.2 m | 47.3 m |
| Cost of revenue | 5.0 m | 6.8 m | 8.1 m | 6.8 m | 7.4 m | 4.2 m | 5.9 m | 5.3 m |
| Gross profit | 48.3 m | -1.3 m | 42.8 m | 42.2 m | 52.8 m | 2.8 m | 44.2 m | 42.0 m |
| Operating income | -4.0 m | -6.0 m | -1.2 m | -2.3 m | -2.0 m | -6.2 m | -8.9 m | -7.1 m |
| Interest expense | 558.6 k | 607.7 k | 463.6 k | 660.8 k | 262.5 k | -190.8 k | -56.5 k | -45.7 k |
| Pre-tax income | -4.6 m | -6.6 m | -1.6 m | -3.0 m | -3.4 m | -6.0 m | -8.9 m | -7.1 m |
| Income tax | 232.5 k | 365.5 k | — | — | 169.1 k | -123.4 k | — | — |
| Net income | -4.7 m | -4.9 m | -183.8 k | -1.6 m | -3.8 m | 20.0 m | -8.9 m | -7.1 m |
| Diluted EPS | -0.13 | -0.12 ≈ | -0.02 | -0.05 | -0.08 ≈ | 0.43 ≈ | -0.20 | -0.16 |
| Operating cash flow | 6.7 m ≈ | 1.1 m | 3.1 m | 8.6 m ≈ | -147.1 k ≈ | -3.3 m | 444.6 k | -6.9 m ≈ |
| Capex | 447.8 k ≈ | 197.9 k | 117.5 k | 776.7 k ≈ | 821.0 k ≈ | 155.5 k | 105.2 k | 67.8 k ≈ |
| Dividends paid | 776.6 k ≈ | 776.6 k | 776.6 k | 776.6 k ≈ | 776.6 k ≈ | 776.6 k | 776.6 k | 776.6 k ≈ |
| Share repurchases | — | — | — | — | 270.0 k | — | — | — |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.3 m | 12.5 m | 37.3 m | 92.9 m | 119.0 m | 152.5 m | 154.8 m | 194.1 m |
| Revenue YoY | +126.1% | +49.8% | +199.1% | +149.0% | +28.2% | +28.2% | +1.5% | +25.3% |
| Net income | -1.2 m | -3.1 m | -58.6 m | -60.9 m | -45.5 m | -20.6 m | -21.4 m | 14.4 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | -0.60 | 0.25 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -14.9% | -25.2% | -157.3% | -65.6% | -38.3% | -13.5% | -13.8% | 7.4% |
| Free cash flow | unavailable | unavailable | unavailable | -33.3 m | -23.3 m | 8.6 m | 16.0 m | 6.4 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 36.8 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 23.2 m USD
- Total assets
- 70.4 m USD
- Debt / equity
- unavailable
- Current ratio
- 1.25x
- ROE
- unavailable
- ROA
- 19.6%
- FCF margin
- 3.3%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 37.3 m | 92.9 m | 119.0 m | 152.5 m | 154.8 m | 194.1 m | SEC (XBRL)· 10 Mar 2026verified |
| Cost of revenue | 8.9 m | 18.0 m | 18.7 m | 18.9 m | 21.4 m | 27.7 m | SEC (XBRL)· 10 Mar 2026verified |
| Gross profit | 28.4 m | 74.9 m | 100.4 m | 133.6 m | 133.4 m | 166.3 m | SEC (XBRL)· 10 Mar 2026verified |
| Operating income | -57.8 m | -54.3 m | -43.4 m | -14.5 m | -20.4 m | -7.7 m | SEC (XBRL)· 10 Mar 2026verified |
| Interest expense | 1.7 m | 3.0 m | 1.3 m | 2.6 m | 2.2 m | 1.4 m | SEC (XBRL)· 10 Mar 2026verified |
| Pre-tax income | -60.4 m | -61.3 m | -44.7 m | -17.4 m | -22.6 m | -10.2 m | SEC (XBRL)· 10 Mar 2026verified |
| Income tax | 122.5 k | 7.7 k | 360.7 k | 428.0 k | 598.0 k | 45.7 k | SEC (XBRL)· 10 Mar 2026verified |
| Net income | -58.6 m | -60.9 m | -45.5 m | -20.6 m | -21.4 m | 14.4 m | SEC (XBRL)· 10 Mar 2026verified |
| Diluted EPS | — | — | — | — | -0.60 | 0.25 | SEC (XBRL)· 10 Mar 2026verified |
| Weighted average diluted shares | 14.3 m | 27.0 m | 31.0 m | 33.9 m | 41.2 m | 45.1 m | SEC (XBRL)· 10 Mar 2026verified |
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 9.2 m | 41.3 m | 4.0 m | 33.1 m | 35.0 m | 36.8 m | SEC (XBRL)· 10 Mar 2026verified |
| Receivables | 997.8 k | 980.1 k | 2.8 m | 6.3 m | 10.5 m | 9.3 m | SEC (XBRL)· 10 Mar 2026verified |
| Inventories | 1.3 m | 1.6 m | 3.7 m | 2.8 m | 2.8 m | 2.8 m | SEC (XBRL)· 10 Mar 2026verified |
| Current assets | 12.4 m | 44.9 m | 11.3 m | 42.6 m | 52.4 m | 51.8 m | SEC (XBRL)· 10 Mar 2026verified |
| Property, plant & equipment, net | — | 233.8 k | 476.4 k | 476.3 k | 1.4 m | 2.4 m | SEC (XBRL)· 10 Mar 2026verified |
| Goodwill | — | 0 | 8.0 m | — | — | — | SEC (XBRL)· 11 Mar 2024verified |
| Intangibles (excl. goodwill) | 339.8 k | 19.8 k | 3.8 m | 3.0 m | 53.3 k | 262.3 k | SEC (XBRL)· 10 Mar 2026verified |
| Total assets | 13.4 m | 49.9 m | 25.7 m | 58.5 m | 76.1 m | 70.4 m | SEC (XBRL)· 10 Mar 2026verified |
| Accounts payable | 10.4 m | 9.1 m | 10.1 m | 11.1 m | 10.9 m | 14.1 m | SEC (XBRL)· 10 Mar 2026verified |
| Current liabilities | 13.9 m | 22.8 m | 31.4 m | 34.8 m | 67.4 m | 41.6 m | SEC (XBRL)· 10 Mar 2026verified |
| Total liabilities | 14.2 m | 24.1 m | 33.0 m | 52.9 m | 83.7 m | 47.3 m | SEC (XBRL)· 10 Mar 2026verified |
| Equity | -4.5 m | 21.7 m | -11.9 m | 4.2 m | -7.6 m | 23.2 m | SEC (XBRL)· 10 Mar 2026verified |
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -12.1 m | -33.1 m | -22.9 m | 8.8 m | 17.5 m | 8.3 m | SEC (XBRL)· 10 Mar 2026verified |
| Capex | — | 247.4 k | 366.6 k | 203.8 k | 1.5 m | 1.9 m | SEC (XBRL)· 10 Mar 2026verified |
| Free cash flow | — | -33.3 m ≈ | -23.3 m ≈ | 8.6 m ≈ | 16.0 m ≈ | 6.4 m ≈ | SEC (XBRL)· 10 Mar 2026derived |
| Investing cash flow | -798.1 k | -3.4 m | -13.9 m | -8.7 m | -11.5 m | 6.9 m | SEC (XBRL)· 10 Mar 2026verified |
| Financing cash flow | 21.0 m | 68.6 m | -528.2 k | 29.1 m | -4.1 m | -13.4 m | SEC (XBRL)· 10 Mar 2026verified |
| Dividends paid | — | 871.5 k | 3.1 m | 3.1 m | 3.1 m | 3.1 m | SEC (XBRL)· 10 Mar 2026verified |
| Share repurchases | — | — | — | — | — | 270.0 k | SEC (XBRL)· 10 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- score weight coverage: 45.8% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 110.4 m USD
Key indicators
Coverage and freshness
Score by group
46% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · input data missing
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 45.8% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | 0.1% | 75 (vs peers) | 14% |
| FCF conversion · Quality | -5,501.3% | 0 (on a fixed band) | 14% |
| Revenue CAGR 3Y · Growth | 17.7% | 100 (on a fixed band) | 18% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -795.9x | 0 (on a fixed band) | 14% |
| Current ratio · Balance sheet | 0.9x | 9 (on a fixed band) | 9% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -10.0% | 0 (on a fixed band) | 18% |
| Shareholder yield (distributions) · Returns | 3.1% | 44 (on a fixed band) | 14% |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet3/100 · 2/3 factors with a value
- Growth· partial100/100 · 1/2 factors with a value
- Quality38/100 · 2/3 factors with a value
- Returns· partial44/100 · 1/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
LifeMD, Inc. (LFMD). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 194.1 m USD in 2025; YoY growth 25.3%; net margin 0.1%; ROE 6.5%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (score weight coverage: 45.8% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Net margin: 0.1%
- Revenue CAGR 3Y: 17.7%
What contradicts it
- FCF conversion: -5,501.3%
- Interest coverage: -795.9x
- Current ratio: 0.9x
- FCF yield: -10.0%
Not assessed (insufficient data or a ratio without meaning): ROIC, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Payout ratio (FCF).
Versus the vertical median
Services-Offices & Clinics of Doctors of Medicine (SIC 8011) · same industry (4-digit SIC) · compared with 8 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| TDOCTeladoc Health, Inc. | 1.7 bn | — | -11.5% | -6.3% | −1.5% | +24% / −48% |
| STLNStarling Oncology, Inc. | 682.8 m | — | — | -6.2% | +27.8% | +113% / +292% |
| SBCSBC Medical Group Holdings Incorporated | 516.3 m | 10.7 | 19.3% | 28.0% | −15.5% | +41% / −54% |
| CCMConcord Medical Services Holdings Ltd | 463.7 m | — | — | -20.2% | +25.2% | −8% / −65% |
| LFMDLifeMD, Inc. | 110.4 m | — | 6.5% | 0.1% | +25.3% | −59% / −69% |
| AIRSAirSculpt Technologies, Inc. | 103.8 m | — | -12.0% | -7.8% | −15.8% | −59% / −71% |
| BMGLBasel Medical Group Ltd | 8.2 m | — | -169.7% | -94.0% | unavailable | −64% / unavailable |
| AUNAAuna S.A. | — | — | 7.5% | 2.5% | +13.2% | −1% / unavailable |
| HIMSHims & Hers Health, Inc. | 0 | — | -32.0% | -5.5% | +59.0% | −39% / +171% |
1- and 3-year price returns: for LFMD from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 0.03 Total return -99% · Per year -99% | 0.05 Total return -98% · Per year -98% | 0.08 Total return -97% · Per year -97% |
| 3 years | 0.03 Total return -98% · Per year -75% | 0.07 Total return -97% · Per year -69% | 0.11 Total return -95% · Per year -64% |
| 5 years | 0.04 Total return -98% · Per year -55% | 0.09 Total return -96% · Per year -48% | 0.16 Total return -93% · Per year -41% |
- Exit P/E± 0.02
- Net margin± 0.01
- Annual revenue growth± 0.01
- Annual dilution± 0.00
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
LifeMD is a direct-to-patient healthcare company offering virtual medical consultations and pharmacy services through a vertically integrated platform, with revenue built largely on recurring subscriptions. In 2026 the company cut its full-year guidance as it moved away from compounded GLP-1 drugs toward branded ones, and adjusted profitability remains under pressure. Telehealth revenue grew 25% in fiscal 2025 1, and second-quarter 2026 revenue reached 47.3 million USD 3.
SWOT
Strengths
- A vertically integrated model with affiliated doctors, an in-house pharmacy and AI-enabled technology supports a coherent patient experience 1.
- High recurring revenue share provides a predictable base for financial planning 13.
- The balance sheet carried no debt at the end of the second quarter of 2026, with an undrawn credit line 3.
Weaknesses
Opportunities
Risks
- Losses and uncertain profitabilityhigh
The company has reported losses from continuing operations and says it cannot guarantee profitability in the short or long term 1.
- Lowered guidancehigh
Full-year 2026 guidance was reduced, and adjusted results could stay below expectations if the marketing cut does not translate into growth 3.
- Dependence on digital marketingmedium
Customer acquisition relies on social media and online advertising, and changes in algorithms or rules could reduce new patient numbers 1.
- Regulation and compliancemedium
Laws on telehealth, data privacy and drug advertising may be interpreted strictly, and non-compliance could lead to fines 1.
- Artificial intelligence and data securitymedium
Use of AI and cybersecurity incidents could affect patients' medical data and the company's reputation 1.
Investment thesis
What would need to be true (bull case)
- If the move to branded GLP-1 drugs consolidates, margins could rise and longer-duration subscriptions could support more predictable revenue 3.
- Subscriber growth and wider insurance coverage could support a larger patient base 21.
- A debt-free balance sheet and an undrawn credit line give flexibility during the reorganisation 3.
What would break the thesis
- Losses from continuing operations and the reduced guidance could show the transition is costing more than first estimated 13.
- Strong competition and regulatory change could lower prices or the company's market share.
- Reliance on paid advertising could make growth expensive if customer acquisition costs stay high 3.
What to watch
- Delivery against third-quarter revenue and adjusted EBITDA guidanceQ3 2026
- Development of weight management subscribers and the share of multi-month plansQ3 2026
- Fourth-quarter revenue run rate against the targeted 250 million USDQ4 2026
- Contribution of the XYOSTED launch and B2B partnerships to second-half revenue2026
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
LifeMD combines a 50-state affiliated medical group, a wholly-owned pharmacy, laboratory integrations, a patient care center and proprietary AI-enabled technology to deliver longitudinal care. The business centres on subscription-based virtual primary care, which began accepting commercial and government insurance in June 2024 1. Active subscribers reached about 356,000 at June 30, 2026 2. The company has also sold its majority stake in WorkSimpli and now describes itself as a pure-play healthcare company 1.
Recurring subscriptions accounted for about 95% of total revenue in fiscal 2025 1, and about 84% in the second quarter of 2026 3. The drop in that share reflects more one-time product sales rather than a loss of subscribers.
The company has expanded into several verticals, including women's health, testosterone therapy and weight management with branded GLP-1 medicines. Its 2026 plan includes partnerships with drug makers, employers and insurers, some of which are still at the execution stage in the second half of the year.
Segments
Weight management programme
The programme, launched in April 2023, had about 108,000 subscribers at the end of the second quarter of 2026 3. The company says nearly all new patients now start with branded GLP-1 therapies after exiting compounded drugs.
Men's and women's health brands
Rex MD and ShapiroMD cover men's health and hair loss, while the LifeMD brand covers primary care and women's health. The April 2025 acquisition of OHHMD marked the official entry into women's health 1.
Market context
The telehealth and virtual care market is described as immature and volatile, with demand depending on consumer acceptance and reimbursement rules. The company points to a B2B spending pool of about 30 billion USD by pharmaceutical, device and diagnostic companies in the U.S., of which one-third could go to digital solutions 1.
Competition is fragmented: online brands, drugstore chains and independent pharmacies all compete for the same patients. A government online platform launched in February 2026 to offer lower cash prices for GLP-1 drugs could compress prices across the market 1.
Trends
- Shift from compounded to branded GLP-1 drugsmixed
The transition has cut near-term revenue and weighed on profitability, but the company says it could improve margins and long-term retention. If the transition ends as management describes, the effect could turn favourable in the second half of the year 3.
- Insurance coverage expansiontailwind
Wider acceptance of commercial and Medicare coverage could let more patients use services without paying cash. The company plans broad coverage across several payer types, and the network expansion in 2026 is a key item to track 12.
- Marketing cost pressureheadwind
Marketing spending rose sharply in 2025 and early 2026, and customer acquisition costs stayed high. If the planned reduction in spending holds through the second half, pressure on profitability could ease 3.
- Regulation of telehealth and marketingheadwind
Laws on data privacy, drug promotion and telehealth are changing quickly and could limit how the company attracts customers or delivers services. The annual report presents regulatory change as an ongoing risk 1.
Competitive position
The company competes with many online brands in primary care, weight loss, men's and women's health and hair loss. It also competes with drugstore chains and independent pharmacies for prescription fills 1.
Stated advantages are the vertically integrated platform, the dedicated provider network and the patient experience, but the company acknowledges the market is highly competitive and that new entrants could quickly change pricing 1.
- Online telehealth brands
Numerous virtual care platforms compete in the same verticals, with no single leader identified in the sources reviewed 1.
- Drugstore and supermarket chains
Compete on convenience and prices for common medicines, particularly over-the-counter products 1.
- Independent pharmacies
Compete locally with patients who prefer a physical pharmacy to fill prescriptions 1.
- Government drug price platform
A portal launched in February 2026 offers lower cash prices with a focus on GLP-1s and indirectly competes with the company's offer 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- LifeMD (LFMD) Secures AT&T Partnership. Can Free Memberships Produce Paying Patients?Yahoo Finance — News · 20 Sept 2026 · EN
SEC filings
- Current report15 Sept 2026Regulation FD disclosure · Financial statements and exhibits
- Quarterly report05 Aug 2026
- Current report05 Aug 2026Results of operations · Regulation FD disclosure · Financial statements and exhibits
- Current report22 Jun 2026Regulation FD disclosure · Financial statements and exhibits
- Quarterly report06 May 2026
- Current report06 May 2026Results of operations · Regulation FD disclosure · Financial statements and exhibits
- Proxy statement30 Apr 2026
- Current report18 Mar 2026Departure or appointment of officers · Other events · Financial statements and exhibits
- Annual report10 Mar 2026
- Current report09 Mar 2026Results of operations · Regulation FD disclosure · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / LifeMD, Inc. · 10 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / LifeMD, Inc. · 05 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / LifeMD, Inc. · 05 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.